Lidoflazine (CAS 3416-26-0)
QUICK LINKS
Lidoflazine is a compound studied for its biochemical properties and mechanisms of action, particularly its ability to inhibit the uptake of adenosine by various cell types. In research environments, Lidoflazine is used to explore cellular adenosine pathways which play a role in modulating physiological processes such as coronary blood flow and myocardial oxygen consumption. The compound′s role in adenosine modulation makes it an interesting subject in the study of cardiac metabolism and the regulation of coronary circulation. Additionally, Lidoflazine is used as a tool to investigate the protective effects against ischemic injury in myocardial tissues in an experimental context. Its interaction with ion channels and cellular receptors also garners attention in research focused on the electrophysiological aspects of cardiac function.
Lidoflazine (CAS 3416-26-0) References
- Nucleoside transport inhibition mediates lidoflazine-induced cardioprotection during intermittent aortic crossclamping. | Chang-Chun, C., et al. 1992. J Thorac Cardiovasc Surg. 104: 1602-9. PMID: 1453724
- Improvement of renal preservation by adding lidoflazine to University of Wisconsin solution. An experimental study in the rat. | Jacobsson, J., et al. 1992. Cryobiology. 29: 305-9. PMID: 1499315
- Lidoflazine is a high affinity blocker of the HERG K(+)channel. | Ridley, JM., et al. 2004. J Mol Cell Cardiol. 36: 701-5. PMID: 15135665
- Lidoflazine in the treatment of comatose survivors of cardiac arrest. | Engler, RL. 1991. N Engl J Med. 325: 1046-7. PMID: 1886630
- Does if control normal automatic rate in canine cardiac Purkinje fibers? Studies on the negative chronotropic effects of lidoflazine. | Dangman, KH. and Miura, DS. 1987. J Cardiovasc Pharmacol. 10: 332-40. PMID: 2444783
- Treatment for calcium channel blocker poisoning: a systematic review. | St-Onge, M., et al. 2014. Clin Toxicol (Phila). 52: 926-44. PMID: 25283255
- Cardiovascular Profile of Xanthone-Based 1,4 Dihydropyridines Bearing a Lidoflazine Pharmacophore Fragment. | Bisi, A., et al. 2018. Molecules. 23: PMID: 30486354
- Lidoflazine does not improve neurologic outcome when administered after complete cerebral ischemia in primates. | Fleischer, JE., et al. 1987. J Cereb Blood Flow Metab. 7: 366-71. PMID: 3584269
- Lidoflazine and propranolol combination treatment in chronic stable angina. | Charlap, S., et al. 1985. Angiology. 36: 240-52. PMID: 4025935
- Studies on the possible mechanisms of lidoflazine arrhythmogenicity. | Keren, G., et al. 1984. J Am Coll Cardiol. 4: 742-7. PMID: 6481014
- Amelioration of brain damage by lidoflazine after prolonged ventricular fibrillation cardiac arrest in dogs. | Vaagenes, P., et al. 1984. Crit Care Med. 12: 846-55. PMID: 6488823
- Cardioprotective effects of lidoflazine during 1-hour normothermic global ischemia. | Flameng, W., et al. 1981. Circulation. 64: 796-807. PMID: 7273379
- Inhibitory effect of lidoflazine on contractions of isolated canine coronary arteries caused by norepinephrine, 5-hydroxytryptamine, high potassium, anoxia and ergonovine maleate. | Van Neuten, JM., et al. 1980. J Pharmacol Exp Ther. 213: 179-87. PMID: 7359366
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lidoflazine, 5 mg | sc-255253 | 5 mg | $188.00 |